Skip to main content
. 2017 Dec 14;2017:8927473. doi: 10.1155/2017/8927473

(a).

Silent CHD/ischaemia screening studies
Study name Screening method Patients (n) Age (years) Smoking (%) Statin use (%) Aspirin use (%) Mean follow-up (years) Silent CHD-ischaemia (%) Main outcome
Faglia et al. ([116]) Exercise ECG and dipyridamole-stress echo 71 58.7 ± 8.3 46 28 9 4.4 21.4 In the screened arm, the proportion of all events (P = 0.018) as well as the proportion of major to minor events (P = 0.006) was significantly less
No screening 70 61.5±8.1 55 21 12 NA
DIAD (Young et al. [117]) Stress scintigraphy 561 60.7 ± 6.7 10 37 43 4.8 22 No difference in cardiac death or nonfatal MI (HR): 0.88; 95% CI: 0.44–1.88; P = 0.73
No screening 562 60.8 ± 6.4 9 41 46 NA
DYNAMIT (Lièvre et al. [118]) Bicycle exercise test or stress scintigraphy 316 64.1 ± 6.4 17 33 39 3.5 21.5 No difference in composite primary endpoint (death from all causes, nonfatal MI, nonfatal stroke, or heart failure requiring emergency intervention) between the screening and the nonscreening group (2.6% versus 2.4% annually; adjusted HR: 1.0; 95% CI: 0.59–1.71)
No screening 315 63.7 ± 6.4 14 36 24 NA
FACTOR-64 (Muhlestein et al. [119]) Coronary CT angiogram (CCTA) 452 61.5 ± 7.9 16 76 43 4.0 69 The primary outcome event rates not significantly different between the CCTA and the control groups (6.2% versus 7.6%; hazard ratio: 0.80 [95% CI: 0.49–1.32]; P = 0.38)
No screening 448 61.6 ± 8.3 15 72 40 NA
DADDY-D (Turrini et al. [120]) Exercise ECG 262 61.9 ± 4.8 40 39 29 3.6 7.6 No difference in cardiac events (HR = 0.85, 95% CI: 0.39–1.83, P = 0.678) or occurrence of first HF episode (HR = 0.27, 95% CI: 0.06–1.31, P = 0.083)
No screening 258 62 ± 5.1 37 44 25 NA